Improved Antitumor Outcomes for Colon Cancer Using Nanomicelles Loaded with the Novel Antitumor Agent LA67

References

• Inés M, Cristina S-D-D, Alberto PD, Elena C, María RY. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197. doi:10.3390/ijms18010197
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015. JAMA Oncol. 2017;3(4):524. doi:10.1001/jamaoncol.2016.568827918777
   PubMed Web of Science ®Google Scholar
• Lin CC, Calvo E, Papadopoulos KP, et al. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009;63(6):1065–1071. doi:10.1007/s00280-008-0811-x18795291
   PubMed Web of Science ®Google Scholar
• Chung HH, Jang BI. A perspective: role of targeted therapy in colon cancer. Korean J Gastroenterol. 2013;61(3):128–135. doi:10.4166/kjg.2013.61.3.12823575231
   PubMedGoogle Scholar
• Huang K-Y, Kao S-H, Wang W-L, et al. Small molecule T315 promotes casitas B-lineage lymphoma–dependent degradation of epidermal growth factor receptor via Y1045 autophosphorylation. Am J Respir Crit Care Med. 2016;193(7):753. doi:10.1164/rccm.201502-0250OC26583948
   PubMed Web of Science ®Google Scholar
• Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):JCO.2015.2065.3949. doi:10.1200/JCO.2015.65.3949
   Web of Science ®Google Scholar
• Beretta GL, Mantegazza F, Misiak M. Methods for elucidation of DNA-anticancer drug interactions and their applications in the development of new drugs. Curr Pharm Des. 2016;22(44):6596–611.27587197
   PubMed Web of Science ®Google Scholar
• Chen BJ. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma. 2001;42(3):253–265. doi:10.3109/1042819010906458211699390
   PubMed Web of Science ®Google Scholar
• Shi X, Jin Y, Cheng C, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res. 2009;15(5):1686. doi:10.1158/1078-0432.CCR-08-214119240172
   PubMed Web of Science ®Google Scholar
• Chan E, Cheng S, Sin F, Xie Y. Triptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. Toxicol Lett. 2001;122(1):81–87. doi:10.1016/S0378-4274(01)00353-811397559
   PubMed Web of Science ®Google Scholar
• Fidler JM, Li K, Chung C, Wei K, Rosen GD. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther. 2003;2(9):855–862.14555704
   PubMed Web of Science ®Google Scholar
• Frese S, Pirnia F, Miescher D, et al. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene. 2003;22(35):5427–5435. doi:10.1038/sj.onc.120684212934102
   PubMed Web of Science ®Google Scholar
• Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res. 2002;8(8):2666–2674.12171899
   PubMed Web of Science ®Google Scholar
• Tengchaisri T, Chawengkirttikul R, Rachaphaew N, Reutrakul V, Sangsuwan R, Sirisinha S. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett. 1998;133(2):169–175. doi:10.1016/S0304-3835(98)00222-510072166
   PubMed Web of Science ®Google Scholar
• Wei YS, Adachi I. Inhibitory effect of triptolide on colony formation of breast and stomach cancer cell lines. Zhongguo Yao li Xue Bao. 1991;12(5):406.1819894
   PubMed Web of Science ®Google Scholar
• Yang S, Chen J, Guo Z, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003;2(12):65.12533674
   PubMedGoogle Scholar
• Zhou GX, Ding XL, Huang JF, et al. Apoptosis of human pancreatic cancer cells induced by triptolide. World J Gastroenterol. 2008;14(10):1504–1509. doi:10.3748/wjg.14.150418330938
   PubMed Web of Science ®Google Scholar
• Shamon LA, Pezzuto JM, Graves JM, et al. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett. 1997;112(1):113–117. doi:10.1016/S0304-3835(96)04554-59029176
   PubMed Web of Science ®Google Scholar
• Li Z, Zhou Z-L, Miao Z-H, et al. Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents. J Med Chem. 2009;52(16):5115–5123. doi:10.1021/jm900342g19637874
   PubMed Web of Science ®Google Scholar
• Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol. 2011;11(3):377–383. doi:10.1016/j.intimp.2011.01.01221255694
   PubMed Web of Science ®Google Scholar
• Xu H, Tang H, Feng H, Li Y. Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide. Eur J Med Chem. 2014;73:46–55. doi:10.1016/j.ejmech.2013.11.04424378709
   PubMed Web of Science ®Google Scholar
• Yu DQ, Zhang DM, Wang HB, Liang XT. Structure modification of triptolide, a diterpenoid from Tripterygium wilfordii. Acta Pharmaceutica Sinica. 1992;27(11):830–836.1300027
   PubMedGoogle Scholar
• Zhang D, Zang Y, Chen X, et al. Triptolide derivatives, their preparation and use. China. 2018;5–16.
   Google Scholar
• Mirrahimi M, Khateri M, Beik J, et al. Enhancement of chemoradiation by co-incorporation of gold nanoparticles and cisplatin into alginate hydrogel. J Biomed Mater Res B Appl Biomater. 2019;107(8):2658–2663. doi:10.1002/jbm.b.3435630864237
   PubMed Web of Science ®Google Scholar
• Montazerabadi A, Beik J, Irajirad R, et al. Folate-modified and curcumin-loaded dendritic magnetite nanocarriers for the targeted thermo-chemotherapy of cancer cells. Artif Cells Nanomed Biotechnol. 2019;47(1):330–340. doi:10.1080/21691401.2018.155767030688084
   PubMed Web of Science ®Google Scholar
• Beik J, Khateri M, Khosravi Z, et al. Gold nanoparticles in combinatorial cancer therapy strategies. Coord Chem Rev. 2019;387:299–324. doi:10.1016/j.ccr.2019.02.025
   Web of Science ®Google Scholar
• Wang Y, Liu T, Li H. Enhancement of triptolide-loaded micelles on tumorigenicity inhibition of human ovarian cancer. J Biomater Sci Polymer Ed. 2016;27(7):545–556. doi:10.1080/09205063.2015.1131667
   PubMed Web of Science ®Google Scholar
• Xu L, Chen H, Xu H, Yang X. Anti-tumour and immuno-modulation effects of triptolide-loaded polymeric micelles. Eur J Pharm Biopharm. 2008;70(3):741–748.18761405
   PubMed Web of Science ®Google Scholar
• Zhou Z, Tang J, Sun Q, Murdoch WJ, Shen Y. A multifunctional PEG–PLL drug conjugate forming redox-responsive nanoparticles for intracellular drug delivery. J Mater Chem B. 2015;3(38):7594–7603. doi:10.1039/C5TB01027F32262643
   PubMed Web of Science ®Google Scholar
• Gao Y-E, Ma X, Hou M, et al. Highly cell-penetrating and ultra-pH-responsive nanoplatform for controlled drug release and enhanced tumor therapy. Colloids Surf B Biointerfaces. 2017;159:484. doi:10.1016/j.colsurfb.2017.08.01828841498
   PubMed Web of Science ®Google Scholar
• Lehner R, Wang X, Marsch S, Hunziker P. Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application. Nanomed Nanotechnol Biol Med. 2013;9(6):742–757. doi:10.1016/j.nano.2013.01.012
   PubMed Web of Science ®Google Scholar
• Tomii Y. Lipid formulation as a drug carrier for drug delivery. Curr Pharm Des. 2002;8(6):467–474. doi:10.2174/138161202339587112069383
   PubMed Web of Science ®Google Scholar
• Wang B, Friess W. Spray drying of silica microparticles for sustained release application with a new sol-gel precursor. Int J Pharm. 2017;532(1):281. doi:10.1016/j.ijpharm.2017.09.01628890172
   PubMedGoogle Scholar
• Niaz T, Hafeez Z, Imran M. Prospectives of antihypertensive nano-ceuticals as alternative therapeutics. Curr Drug Targets. 2016;17(11):1269–1280.
   Google Scholar
• Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10(11):3708–3716.15173077
   PubMed Web of Science ®Google Scholar
• Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108(2):241–250. doi:10.1007/s10549-007-9591-y17476588
   PubMed Web of Science ®Google Scholar
• Yang XL, Yang YJ, Xu HB, et al. Research progress of triptolide-loaded nanoparticles delivery systems. Mater Sci Eng C Mater Biol Appl. 2005;5(2):138–142.
   Google Scholar
• Zheng Q, Gong T, Sun X, Zhang Z-R. Synthesis, characterization and in vitro evaluation of triptolide-lysozyme conjugate for renal targeting delivery of triptolide. Arch Pharm Res. 2006;29(12):1164–1170. doi:10.1007/BF0296930917225468
   PubMed Web of Science ®Google Scholar
• Li Y, Yang F, Chen W, et al. A novel monomethoxy polyethylene glycol^|^#8211;polylactic acid polymeric micelles with higher loading capacity for docetaxel and well-reconstitution characteristics and its anti-metastasis study. Chem Pharm Bull (Tokyo). 2012;60(9):1146–1154. doi:10.1248/cpb.c12-0032322976323
   PubMed Web of Science ®Google Scholar
• Chen L, Huang W, Gao Z, Fang W, Jin M. Lx2-32c–loaded polymeric micelles with small size for intravenous drug delivery and their inhibitory effect on tumor growth and metastasis in clinically associated 4T1 murine breast cancer. Int J Nanomedicine. 2016;11:5457–5742. doi:10.2147/IJN.S11634727799769
   PubMed Web of Science ®Google Scholar
• Moughton AO, Hillmyer MA, Lodge TP. Multicompartment block polymer micelles. Macromolecules. 2012;45(1):2–19. doi:10.1021/ma201865s
   Web of Science ®Google Scholar
• Valenzuelaoses JK, García MC, Feitosa VA, et al. Development and characterization of miltefosine-loaded polymeric micelles for cancer treatment. Mater Sci Eng C. 2017;81:327. doi:10.1016/j.msec.2017.07.040
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ren T, Gou J, et al. Strategies for improving the payload of small molecular drugs in polymeric micelles. J Control Release. 2017;261:S0168365917300548. doi:10.1016/j.jconrel.2017.01.047
   Web of Science ®Google Scholar
• Zhulina EB, Borisov OV. Theory of block polymer micelles: recent advances and current challenges. Macromolecules. 2012;45(11):4429–4440. doi:10.1021/ma300195n
   Web of Science ®Google Scholar
• Bae Y, Alani AWG, Rockich NC, Lai TSZC, Kwon GS. Mixed pH-sensitive polymeric micelles for combination drug delivery. Pharm Res. 2010;27(11):2421–2432. doi:10.1007/s11095-010-0234-320700632
   PubMed Web of Science ®Google Scholar
• Wang J, Xu W, Li S, et al. Polylactide-cholesterol stereocomplex micelle encapsulating chemotherapeutic agent for improved antitumor efficacy and safety. J Biomed Nanotechnol. 2018;14(12):2102–2113. doi:10.1166/jbn.2018.262430305217
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao P, Su W, et al. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials. 2010;31(33):8741–8748. doi:10.1016/j.biomaterials.2010.07.08220727587
   PubMed Web of Science ®Google Scholar
• Simonoska Crcarevska M, Geskovski N, Calis S, et al. Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO–PPO–PEO nanoparticles using OFAT experiments. Eur J Pharm Sci. 2013;49(1):65–80. doi:10.1016/j.ejps.2013.02.00423439240
   PubMed Web of Science ®Google Scholar
• Meng L, Chu X, Xing H, et al. Improving glioblastoma therapeutic outcomes via doxorubicin-loaded nanomicelles modified with borneol. Int J Pharm. 2019;567:118485. doi:10.1016/j.ijpharm.2019.11848531260781
   PubMedGoogle Scholar
• Venkatesan P, Puvvada N, Dash R, et al. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials. 2011;32(15):3794–3806. doi:10.1016/j.biomaterials.2011.01.02721392822
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010;624:25–37.20217587
   PubMedGoogle Scholar
• Maeda H. Polymer therapeutics and the EPR effect. J Drug Target. 2017;25(9–10):781–785. doi:10.1080/1061186X.2017.136587828988499
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151. doi:10.1016/j.addr.2010.04.00920441782
   PubMed Web of Science ®Google Scholar
• Jeong W-J. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol. 2014;20(29):9862. doi:10.3748/wjg.v20.i29.986225110417
   PubMed Web of Science ®Google Scholar
• Qin X, Xu J, Ren L, et al. Analysis of chinese guidelines for diagnosis and comprehensive treatment of liver metastasis from colorectal cancer (V 2016). J Clin Surg. 2017;25(1):15–20.
   Google Scholar
• Zheng S, Zhang S, Huang Y. Retrospect and current status of research on colorectal cancer in the past 30 years. J Pract Oncol. 2016;31(1):2–5.
   Google Scholar